Nivolumab plus ipilimumab with chemotherapy for non–small cell lung cancer with untreated brain metastases: A multicenter single-arm phase 2 trial (NIke, LOGiK 2004)
European Journal of Cancer · 2024
DOI: 10.1016/j.ejca.2024.115052 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift European Journal of Cancer, 2024. Verfasst von Yuko Tsuchiya-Kawano und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Kitakyushu Municipal Medical Center, 2-1-1 Bashaku, Kokurakita-ku, Kitakyushu, Fukuoka 802-0077, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Nivolumab, Ipilimumab, Lung Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: Bristol-Myers Squibb, Bristol-Myers Squibb Foundation, Ono Pharmaceutical Co Ltd.
Themen: Onkologische Pflege
Abstract (Originalsprache)
BACKGROUND: The effect of dual immunotherapy combined with platinum-based chemotherapy on untreated brain metastases derived from non-small cell lung cancer (NSCLC) has remained unclear. METHODS: This multicenter single-arm phase 2 study enrolled patients with chemotherapy-naïve advanced NSCLC and at least one brain metastasis ≥ 5 mm in size that had not been previously treated. Patients received nivolumab plus ipilimumab combined with platinum-doublet chemotherapy (two cycles), followed by nivolumab-ipilimumab alone. The primary endpoint of the study was intracranial response rate as determined by modified Response Evaluation Criteria in Solid Tumors (RECIST) for brain metastases of ≥ 5 mm as target lesions. RESULTS: A total of 30 patients from 18 institutions was enrolled in this study. The median age was 66.5 years (range, 47-83 years), and 26 patients (87 %) had a non-squamous cell carcinoma histology. The median size of all target brain lesions was 8.4 mm, with a range of 5-39 mm. The intracranial response rate assessed by modified RECIST was 50.0 % (95 % CI, 33.2-66.8 %), with the rate of complete response being 20.0 %, and the study met its primary endpoint. The systemic response rate was 53.3 % (95 % CI, 36.1-69.8 %), and responses for intracranial and extracranial lesions were generally consistent. The median intracranial progression-free survival was 8.1 months, and both the median intracranial duration of response and time to brain radiotherapy were not reached. CONCLUSION: Nivolumab plus ipilimumab combined with platinum-based chemotherapy showed promising intracranial activity in NSCLC patients with untreated brain metastases. TRIAL REGISTRATION: jRCT071210019.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory Medicine, Kitakyushu Municipal Medical Center, 2-1-1 Bashaku, Kokurakita-ku, Kitakyushu, Fukuoka 802-0077, Japan.
- Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan.
- Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo 650-0017, Japan.
- Department of Respiratory Medicine, Tohoku University, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi 980-8574, Japan.
- Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, 3-1-1 Notame, Minami-ku, Fukuoka 811-1395, Japan.
- Department of Respiratory Medicine, Nagasaki Prefecture Shimabara Hospital, 7895 Shimokawashiri-machi, Shimabara, Nagasaki 855-0861, Japan.
Förderung
- Bristol-Myers Squibb
- Bristol-Myers Squibb Foundation
- Ono Pharmaceutical Co Ltd
Zitieren
APA
Tsuchiya-Kawano, Y., Shiraishi, Y., Tanaka, K., Tachihara, M., Saito, R., Okamoto, T., Sugasaki, N., Nakatomi, K., Kiyomi, F., & Okamoto, I. (2024). Nivolumab plus ipilimumab with chemotherapy for non–small cell lung cancer with untreated brain metastases: A multicenter single-arm phase 2 trial (NIke, LOGiK 2004). European Journal of Cancer. https://doi.org/10.1016/j.ejca.2024.115052
Vancouver
Tsuchiya-Kawano Y, Shiraishi Y, Tanaka K, Tachihara M, Saito R, Okamoto T, et al. Nivolumab plus ipilimumab with chemotherapy for non–small cell lung cancer with untreated brain metastases: A multicenter single-arm phase 2 trial (NIke, LOGiK 2004). European Journal of Cancer. 2024. doi:10.1016/j.ejca.2024.115052
BibTeX
@article{TsuchiyaKawano2024,
author = {Tsuchiya-Kawano, Yuko and Shiraishi, Yoshimasa and Tanaka, Kentaro and Tachihara, Motoko and Saito, Ryota and Okamoto, Tatsuro and Sugasaki, Nanae and Nakatomi, Keita and Kiyomi, Fumiaki and Okamoto, Isamu},
title = {Nivolumab plus ipilimumab with chemotherapy for non–small cell lung cancer with untreated brain metastases: A multicenter single-arm phase 2 trial (NIke, LOGiK 2004)},
journal = {European Journal of Cancer},
year = {2024},
doi = {10.1016/j.ejca.2024.115052}
}
EUVIMED